Impact of dialysis modality on major adverse cardiovascular events and all-cause mortality: a national population-based study. Issue 5 (12th December 2020)

• Record Type: Journal Article
• Authors: Hu, Ping-Jen; Chen, Yu-Wei; Chen, Tzu-Ting; Sung, Li-Chin; Wu, Mei-Yi; Wu, Mai-Szu
• Is Part Of: Nephrology dialysis transplantation. Volume 36:Issue 5(2021)
• Page Start: 901
• Page End: 908
• Publication Date: 2020-12-12
• Subjects: dialysis modality -- hemodialysis -- major adverse cardiovascular events -- peritoneal dialysis; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa282
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background: Only few studies with inconsistent results comparing the relative risk of cardiac mortality between peritoneal dialysis (PD) and hemodialysis (HD). Switches between renal replacement therapy (RRT) modalities render objective assessment of survival benefits a greater challenge. Methods: Data were retrieved from Taiwan's National Health Insurance Database from 1 January 2006 to 31 December 2015. We included 13 662 and 41 047 long-term dialysis patients in a propensity score matching study design and a time-varying study design, respectively, to compare major adverse cardiovascular events (MACEs) between patients receiving PD and HD. We also included 109 256 dialysis patients to compare the all-cause mortality among different RRT modalities. Results: For MACE, the hazard ratio (HR) for PD patients compared to HD patients was 0.95 [95% confidence interval (CI) 0.89–1.02] in the propensity score study design and 1.06 (95% CI 1.01–1.12) in the time-varying study design. For all-cause mortality, the HR for PD patients compared to HD patients was 1.09 (95% CI 1.05–1.13) in the propensity score study design and 1.13 (95% CI 1.09–1.17) in the time-varying study design. The HR for death was higher at a level of statistical significance for females (1.21, 95% CI 1.15–1.28), patients ≥65 years old (1.30, 95% CI 1.24–1.36) and diabetes mellitus (DM; 1.28, 95% CI 1.22–1.34). Conclusions: The HR for MACE is significantly higher among PD patients in time-varying design analysis. In addition, all-cause mortality was higher in PD patients compared to patients with HD, especially in those who were aged ≥65 years, female or DM.